TrialScientific reports2024

Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.

Bartomeu Fullana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.